News & Events

In a collaboration between researchers in Norway (Oslo University Hospital/University of Oslo and Nextera AS), USA (John Hopkins University) and Australia (Monash University), Nextera’s unique NextCore-Ab technology was employed to generate and characterize extremely sensitive TCR-Like antibodies towards gluten T cell epitopes. Their utility expand insight into celiac disease pathogenesis and opens the door for targeted therapeutic intervention

In ChemBioChem we describe the employment of Nextera’s pVII peptide phage display technology in the fine-mapping of FSAP enzyme substrate specificity, which shows surprising new results.